PT-141 (Bremelanotide)

Mechanism of action

PT-141 (bremelanotide) is a cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) developed by Palatin Technologies through systematic medicinal chemistry optimisation of Melanotan II, which was itself a stabilised cyclic analogue of α-MSH. The molecular design goal was to preserve the central-nervous-system sexual-function effects of Melanotan II while reducing the pigmentation activity through modified MC1R engagement. The result is a compound with retained agonism at MC3R, MC4R, and MC5R with reduced but still-present MC1R activity — a relative receptor-selectivity shift toward the central sexual-function receptors. The principal pharmacological mechanism responsible for the sexual-function effects involves MC4R activation in central neural circuits regulating sexual arousal and libido. The relevant neural substrates include hypothalamic paraventricular nucleus, medial preoptic area, and brainstem sexual-function centres including the periaqueductal gray. MC4R activation in these circuits drives sexual arousal, sexual desire, and (in males) erectile response through mechanisms fundamentally distinct from the peripheral vascular smooth-muscle relaxation mechanism of PDE5 inhibitors. Rather than acting on erectile tissue directly, PT-141 acts on central circuits that generate the arousal response, of which erectile function is a downstream consequence in males. The central-nervous-system mechanism means that PT-141 can produce sexual arousal effects in conditions where PDE5 inhibitors fail — including psychogenic sexual dysfunction, certain organic conditions with intact vascular function but impaired central arousal, and (importantly) female sexual dysfunction where PDE5 inhibitors have limited applicability due to the different vascular pharmacology of female sexual function. The Vyleesi HSDD indication reflects this specifically female sexual-dysfunction context where central-arousal pharmacology has clinical utility. Downstream of MC4R activation, the sexual-function pharmacology involves dopaminergic release in the medial preoptic area and other reward-and-arousal circuits, oxytocin release, and modulation of sexual-behaviour neural circuits. The precise molecular chain is incompletely characterised but the behavioural phenotype is well-established across multiple pre-clinical and clinical studies. Secondary MC4R and MC3R effects contribute to some of the adverse-event profile. MC4R activation affects appetite (typically appetite suppression at the doses used for sexual function, but this is not the licensed indication and effect sizes are modest); MC4R activation on cardiovascular sympathetic circuits produces the modest blood pressure elevation and heart rate increase documented in clinical trials. MC1R activity (reduced from Melanotan II but not eliminated) produces occasional focal skin hyperpigmentation, particularly with repeated dosing. The FDA-licensed Vyleesi dosing regimen is on-demand subcutaneous administration (via pre-filled autoinjector) 45 minutes to a few hours before anticipated sexual activity, up to a maximum of 8 doses per month with at least 24 hours between doses. This 'as-needed' rather than chronic-daily framework matches the acute pharmacology (2.7 hour half-life; 4-6 hour functional effect duration) and reflects the therapeutic goal of enhancing episode-specific sexual arousal rather than producing sustained pharmacological state changes.

PT-141 (bremelanotide) received FDA approval as Vyleesi in June 2019 for hypoactive sexual desire disorder in premenopausal women — the first melanocortin-receptor agonist approved for a sexual-function indication and one of very few pharmacological compounds producing sexual-arousal effects through central-nervous-system rather than peripheral vascular mechanisms.

— Notable finding

Research history

PT-141 was developed by Palatin Technologies through systematic medicinal chemistry programme originating from the observation that Melanotan II (an experimental tanning peptide) produced unexpected sexual-arousal effects in early clinical exploration. The Palatin development sought to optimise this sexual-function pharmacology while reducing the pigmentation activity that was Melanotan II's original intended effect. The medicinal-chemistry effort across the late 1990s and 2000s produced bremelanotide as the lead compound. Early Phase II clinical development explored PT-141 for both male erectile dysfunction and female hypoactive sexual desire disorder using intranasal formulation. The male-erectile-dysfunction development was complicated by cardiovascular safety concerns — modest but consistent blood pressure elevation and heart rate increase — that made the risk-benefit calculation unfavourable versus the well-established PDE5 inhibitor class (sildenafil, tadalafil). The female-HSDD development became the principal focus, reflecting the greater unmet need in that indication where PDE5 inhibitors have limited applicability. The intranasal formulation was discontinued in favour of subcutaneous injection during later development, addressing pharmacokinetic and consistency concerns of the intranasal route. Phase III RECONNECT trials (two pivotal RCTs, approximately 1,200 combined participants) demonstrated efficacy versus placebo in premenopausal women with acquired generalised HSDD, supporting FDA approval. FDA approval of Vyleesi (bremelanotide) came in June 2019 as the second FDA-approved pharmacotherapy specifically for female HSDD (following flibanserin/Addyi in 2015). The FDA labelling includes cardiovascular precautions reflecting the modest blood pressure and heart rate effects. Commercial uptake has been modest, reflecting the specific indication (premenopausal women only, generalised acquired HSDD), the on-demand rather than chronic use paradigm, and the availability of alternative approaches for female sexual dysfunction. European regulatory status is different from FDA. The EMA has not authorised Vyleesi, and MHRA authorisation has not been sought. The compound is not licensed in the UK. Research-chemical PT-141 has substantial grey-market presence, with sexual-function research-chemical-community use predating the Vyleesi FDA approval by over a decade and continuing since. As of 2026, Vyleesi remains commercially available in the US through prescription. Palatin Technologies has continued melanocortin-system research and has advanced additional related compounds through clinical development.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

PT-141 (bremelanotide/Vyleesi) has one of the more thoroughly characterised safety profiles in the sexual-health peptide class, accumulated through the Palatin clinical-development programme and post-marketing surveillance since 2019 FDA approval. The principal documented adverse events include nausea (~40% at licensed dose — the most common adverse event and the principal reason for treatment discontinuation), flushing (~20%), injection-site reactions (~13%), headache (~11%), and occasional focal skin hyperpigmentation with repeated dosing (~1%; more common in individuals with darker baseline skin). The cardiovascular safety profile is the principal specific concern reflected in the FDA labelling. Vyleesi produces modest but consistent transient blood pressure elevation (typical systolic increase of 6 mmHg, diastolic increase of 3 mmHg peaking approximately 3 hours after administration) and modest heart rate elevation. These effects are related to MC4R activation on cardiovascular sympathetic circuits and are dose-dependent. The clinical significance is modest for most patients but the FDA labelling includes contraindication for uncontrolled hypertension and cautions for cardiovascular risk factors. The focal hyperpigmentation effect reflects residual MC1R activity. In some patients repeated dosing produces localised increases in skin pigmentation (particularly on the face, breasts, and gingiva). This is generally reversible on discontinuation but can be problematic cosmetically. The effect is more prominent in individuals with darker baseline skin — a mechanistically expected consequence of MC1R agonism. Sexual-function-related adverse events — including inappropriate or unwanted sexual arousal — have been documented but at low frequency. The FDA labelling advises careful patient selection to ensure the sexual-function pharmacology is appropriate. Serious adverse events specifically attributable to bremelanotide have been uncommon in the clinical-trial and post-marketing experience. Anti-drug antibodies develop in some patients but have not been associated with clinically significant loss of efficacy or safety issues. The on-demand dosing paradigm — maximum 8 doses per month with at least 24 hours between doses — limits cumulative exposure and mitigates the chronic-dosing safety concerns that would apply to daily use. Chronic daily-use safety pharmacology is not characterised because it is not the licensed indication.

UK regulatory status

PT-141 (bremelanotide/Vyleesi) is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no UK marketing authorisation. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women in the United States; the EMA has not authorised it in Europe. UK authorisation has not been sought. It is not a controlled substance under the Misuse of Drugs Act 1971. Research-grade material for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration of PT-141 to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence — the FDA approval does NOT authorise UK supply or use. Specialist UK access through the unlicensed-medicines 'specials' route (Regulation 167) is theoretically possible for individual patients with HSDD, typically through importation of Vyleesi from US pharmacies. In practice this route is rarely pursued given the availability of alternative approaches for female sexual dysfunction and the specific FDA-labelled patient population. PT-141 is not currently on the WADA Prohibited List. Its sexual-function mechanism does not fall within any current WADA category, though athletes should verify the current annual Prohibited List. For animal research under ASPA, PT-141 work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

Frequently asked questions